Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29790938 | 1.00 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL7170554 | 0.85 | NR4A2 (0.57) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL730525 | 0.84 | NR4A2 (0.69) | GABRA1GABRB2LMNAPKMPBRM1 | |
| Hydrochloric Acid SCHEMBL28308377 | 0.83 | NR4A2 (0.67) | GABRA1GABRB2LMNAPKMPBRM1 | |
| Hydrochloric Acid SCHEMBL30718988 | 0.83 | NR4A2 (0.67) | GABRA1GABRB2LMNAPKMPBRM1 | |
| SCHEMBL10981156 | 0.83 | PKM (0.52) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL10981136 | 0.83 | PKM (0.52) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL20913000 | 0.83 | LMNA (0.59) | LMNAPKMPBRM1NR4A2CREBBP | |
| SCHEMBL30658176 | 0.83 | NR4A2 (0.71) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL729076 | 0.83 | NR4A2 (0.71) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011526618-A | — | — | 2011-10-13 | — | — | JP | claimed |
| US-20110166136-A1 | Calcium Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2011-07-07 | — | — | US | claimed |
| EP-2303840-A2 | CALCIUM ION CHANNEL MODULATORS&USES THEREOF | Lectus Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | claimed |
| WO-2010001179-A2 | CALCIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | WO | claimed |
| EP-3749306-B1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV INDIANA TRUSTEES (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030901-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV INDIANA TRUSTEES (US) | 2023-04-20 | — | — | US | disclosed |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-11578060-B2 | JAK3 selective inhibitor | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-02-14 | — | — | US | disclosed |
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20210214344-A1 | JAK3 SELECTIVE INHIBITOR | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-0122157-A2 | Improvements in or relating to indolylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4118394-A | ANTIULCER, ANTIDEPRESSANT | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1978-10-03 | — | — | US | disclosed |
| US-4066780-A | Pyranoindole derivatives as antiulcer agents | AYERST MCKENNA AND HARRISON LTD. (CA) | 1978-01-03 | — | — | US | disclosed |
| US-4066779-A | ANTIDEPRESSANT, ANTIULCER | AYERST, MCKENNA AND HARRISON LTD. (CA) | 1978-01-03 | — | — | US | disclosed |
| US-4056538-A | ANTIDEPRESSANTS, ANTIULCER AGENTS | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1977-11-01 | — | — | US | disclosed |
| US-4056537-A | CYCLIZATION, ACID CATALYST | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-11-01 | — | — | US | disclosed |
| US-4041169-A | TREATING AND PREVENTING ULCERS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-08-09 | — | — | US | disclosed |
| US-4003913-A | ANTIDEPRESSANTS, ANTIULCER AGENTS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | GABRA1 3206/4885GABRG2 3313/4885GABRB3 2931/4885 |
| US-12030901-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | NAMPT, NNT, NAPRT | GABRA1 3708/4885GABRG2 4356/4885GABRB3 3429/4885 |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | GABRA1 3708/4885GABRG2 4356/4885GABRB3 3429/4885 |
| US-20110166136-A1 | Calcium Ion Channel Modulators & Uses Thereof | CACNA1E, CACNA1B, KCNN3 | GABRA1 285/4885GABRG2 358/4885GABRB3 278/4885 |
| US-20210214344-A1 | JAK3 SELECTIVE INHIBITOR | JAK3, JAK1, JAK2 | GABRA1 2517/4885GABRG2 2684/4885GABRB3 1450/4885 |
| US-11578060-B2 | JAK3 selective inhibitor | JAK3, JAK1, JAK2 | GABRA1 2517/4885GABRG2 2684/4885GABRB3 1450/4885 |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | NAMPT, NNT, NAPRT | GABRA1 3708/4885GABRG2 4356/4885GABRB3 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.